Tumor-derived TGF-β inhibits DC migration to dLNs by reducing CCR7 expression, and TGF-β neutralization via conventional or bispecific antibodies increases functional DC populations in the TME [59, 70]. The gene discussed is TGFB1; the disease is neoplasm.